Bevacizumab for retinopathy of prematurity

Ophthalmology

Volumn 119, Issue 5, 2012, Pages

  Stewart, Michael W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; HYPOXIA INDUCIBLE FACTOR 2ALPHA; LUNG SURFACTANT; VASCULOTROPIN;

DEATH; DRUG HALF LIFE; DRUG SAFETY; HUMAN; INFANT; INFANT MORTALITY; LETTER; MOLECULAR WEIGHT; NONHUMAN; PREMATURITY; PRIORITY JOURNAL; RECURRENT DISEASE; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY FAILURE; RETROLENTAL FIBROPLASIA;

EID: 84860460060     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2012.01.056     Document Type: Letter

References (5)

1. D.M. Moshfeghi, A.M. Berrocal Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice Ophthalmology 118 2011 1227 1228
2. H.A. Mintz-Hittner, K.A. Kennedy, A.Z. Chuang Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity N Engl J Med 364 2011 603 615
3. S. Bakri, M.R. Snyder, J.M. Reid Pharmacokinetics of intravitreal bevacizumab (Avastin) Ophthalmology 114 2007 855 859 (Pubitemid 46635858)
4. M. Tolentino Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease Surv Ophthalmol 56 2011 95 113
5. V. Compernolle, K. Brusselmans, T. Acker Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice Nat Med 8 2002 702 710 (Pubitemid 34778723)